The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion

Paula Q. Barrett, Carlos M Isales

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Using freshly isolated bovine adrenal glomerulosa cells we examined the inhibitory effect of atrial natriuretic peptide (ANP) on aldosterone secretion stimulated by agonists that use either the Ca2+-phosphoinositide or cAMP messenger system. In a continuous perifusion system, angiotensin II (All) induces a prompt initial rise in aldosterone secretion, followed by a sustained secretory response. Both phases of secretion are rapidly and independently inhibited by ANP. The role of two cyclic nucleotides, cGMP and cAMP, as mediators of this ANPinduced inhibition was examined. The effect of 8-bromo-cGMP (1–100 μM) or (Bu)2cGMP (1–50 μM) on the All-stimulated rate of secretion was studied in a perifusion system. Either analog, whether added early or late, maximally inhibited by 20–30% only the late or sustained phase of aldosterone secretion. The effect of ANP on cellular cAMP content was examined in a static incubation system. Although ANP caused a reduction in the cAMP content of cells stimulated with either All or ACTH, it had little or no effect on the cAMP levels in cells stimulated with carbachol. In All- and ACTH-stimulated cells, the relationship between reduced cAMP content and reduced secretion was explored. In the All-stimulated cell inhibited by ANP, simple restoration of cAMP content with forskolin did not restore the secretory rate. Pertussis toxin treatment blocked the inhibitory effect of ANP on cAMP content, but did not block its inhibition of secretion. In the ACTH-stimulated cell, reversal of the ANP-induced reduction of cAMP with forskolin, partially restored the stimulated rate of secretion, although restoration of cAMP with a 10-fold higher dose of ACTH did not restore the stimulated rate of secretion in the presence of ANP. These results imply that both the ANP-induced rise in cGMP and the ANP-induced decrease in cellular cAMP content may contribute to the inhibition of steroidogenesis. However, these inhibitory messages do not induce either the magnitude or the temporal pattern of inhibition induced by ANP. Thus, in the adrenal multiple messenger systems may underlie the action of ANP.

Original languageEnglish (US)
Pages (from-to)799-808
Number of pages10
JournalEndocrinology
Volume122
Issue number3
DOIs
StatePublished - Mar 1 1988

Fingerprint

Cyclic Nucleotides
Atrial Natriuretic Factor
Aldosterone
Adrenocorticotropic Hormone
Colforsin
Secretory Rate
Zona Glomerulosa
Pertussis Toxin
Carbachol
Phosphatidylinositols
Angiotensin II

ASJC Scopus subject areas

  • Endocrinology

Cite this

The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion. / Barrett, Paula Q.; Isales, Carlos M.

In: Endocrinology, Vol. 122, No. 3, 01.03.1988, p. 799-808.

Research output: Contribution to journalArticle

@article{0cb72ed8e3544570b06c4681d0c24e82,
title = "The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion",
abstract = "Using freshly isolated bovine adrenal glomerulosa cells we examined the inhibitory effect of atrial natriuretic peptide (ANP) on aldosterone secretion stimulated by agonists that use either the Ca2+-phosphoinositide or cAMP messenger system. In a continuous perifusion system, angiotensin II (All) induces a prompt initial rise in aldosterone secretion, followed by a sustained secretory response. Both phases of secretion are rapidly and independently inhibited by ANP. The role of two cyclic nucleotides, cGMP and cAMP, as mediators of this ANPinduced inhibition was examined. The effect of 8-bromo-cGMP (1–100 μM) or (Bu)2cGMP (1–50 μM) on the All-stimulated rate of secretion was studied in a perifusion system. Either analog, whether added early or late, maximally inhibited by 20–30{\%} only the late or sustained phase of aldosterone secretion. The effect of ANP on cellular cAMP content was examined in a static incubation system. Although ANP caused a reduction in the cAMP content of cells stimulated with either All or ACTH, it had little or no effect on the cAMP levels in cells stimulated with carbachol. In All- and ACTH-stimulated cells, the relationship between reduced cAMP content and reduced secretion was explored. In the All-stimulated cell inhibited by ANP, simple restoration of cAMP content with forskolin did not restore the secretory rate. Pertussis toxin treatment blocked the inhibitory effect of ANP on cAMP content, but did not block its inhibition of secretion. In the ACTH-stimulated cell, reversal of the ANP-induced reduction of cAMP with forskolin, partially restored the stimulated rate of secretion, although restoration of cAMP with a 10-fold higher dose of ACTH did not restore the stimulated rate of secretion in the presence of ANP. These results imply that both the ANP-induced rise in cGMP and the ANP-induced decrease in cellular cAMP content may contribute to the inhibition of steroidogenesis. However, these inhibitory messages do not induce either the magnitude or the temporal pattern of inhibition induced by ANP. Thus, in the adrenal multiple messenger systems may underlie the action of ANP.",
author = "Barrett, {Paula Q.} and Isales, {Carlos M}",
year = "1988",
month = "3",
day = "1",
doi = "10.1210/endo-122-3-799",
language = "English (US)",
volume = "122",
pages = "799--808",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion

AU - Barrett, Paula Q.

AU - Isales, Carlos M

PY - 1988/3/1

Y1 - 1988/3/1

N2 - Using freshly isolated bovine adrenal glomerulosa cells we examined the inhibitory effect of atrial natriuretic peptide (ANP) on aldosterone secretion stimulated by agonists that use either the Ca2+-phosphoinositide or cAMP messenger system. In a continuous perifusion system, angiotensin II (All) induces a prompt initial rise in aldosterone secretion, followed by a sustained secretory response. Both phases of secretion are rapidly and independently inhibited by ANP. The role of two cyclic nucleotides, cGMP and cAMP, as mediators of this ANPinduced inhibition was examined. The effect of 8-bromo-cGMP (1–100 μM) or (Bu)2cGMP (1–50 μM) on the All-stimulated rate of secretion was studied in a perifusion system. Either analog, whether added early or late, maximally inhibited by 20–30% only the late or sustained phase of aldosterone secretion. The effect of ANP on cellular cAMP content was examined in a static incubation system. Although ANP caused a reduction in the cAMP content of cells stimulated with either All or ACTH, it had little or no effect on the cAMP levels in cells stimulated with carbachol. In All- and ACTH-stimulated cells, the relationship between reduced cAMP content and reduced secretion was explored. In the All-stimulated cell inhibited by ANP, simple restoration of cAMP content with forskolin did not restore the secretory rate. Pertussis toxin treatment blocked the inhibitory effect of ANP on cAMP content, but did not block its inhibition of secretion. In the ACTH-stimulated cell, reversal of the ANP-induced reduction of cAMP with forskolin, partially restored the stimulated rate of secretion, although restoration of cAMP with a 10-fold higher dose of ACTH did not restore the stimulated rate of secretion in the presence of ANP. These results imply that both the ANP-induced rise in cGMP and the ANP-induced decrease in cellular cAMP content may contribute to the inhibition of steroidogenesis. However, these inhibitory messages do not induce either the magnitude or the temporal pattern of inhibition induced by ANP. Thus, in the adrenal multiple messenger systems may underlie the action of ANP.

AB - Using freshly isolated bovine adrenal glomerulosa cells we examined the inhibitory effect of atrial natriuretic peptide (ANP) on aldosterone secretion stimulated by agonists that use either the Ca2+-phosphoinositide or cAMP messenger system. In a continuous perifusion system, angiotensin II (All) induces a prompt initial rise in aldosterone secretion, followed by a sustained secretory response. Both phases of secretion are rapidly and independently inhibited by ANP. The role of two cyclic nucleotides, cGMP and cAMP, as mediators of this ANPinduced inhibition was examined. The effect of 8-bromo-cGMP (1–100 μM) or (Bu)2cGMP (1–50 μM) on the All-stimulated rate of secretion was studied in a perifusion system. Either analog, whether added early or late, maximally inhibited by 20–30% only the late or sustained phase of aldosterone secretion. The effect of ANP on cellular cAMP content was examined in a static incubation system. Although ANP caused a reduction in the cAMP content of cells stimulated with either All or ACTH, it had little or no effect on the cAMP levels in cells stimulated with carbachol. In All- and ACTH-stimulated cells, the relationship between reduced cAMP content and reduced secretion was explored. In the All-stimulated cell inhibited by ANP, simple restoration of cAMP content with forskolin did not restore the secretory rate. Pertussis toxin treatment blocked the inhibitory effect of ANP on cAMP content, but did not block its inhibition of secretion. In the ACTH-stimulated cell, reversal of the ANP-induced reduction of cAMP with forskolin, partially restored the stimulated rate of secretion, although restoration of cAMP with a 10-fold higher dose of ACTH did not restore the stimulated rate of secretion in the presence of ANP. These results imply that both the ANP-induced rise in cGMP and the ANP-induced decrease in cellular cAMP content may contribute to the inhibition of steroidogenesis. However, these inhibitory messages do not induce either the magnitude or the temporal pattern of inhibition induced by ANP. Thus, in the adrenal multiple messenger systems may underlie the action of ANP.

UR - http://www.scopus.com/inward/record.url?scp=0023875656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023875656&partnerID=8YFLogxK

U2 - 10.1210/endo-122-3-799

DO - 10.1210/endo-122-3-799

M3 - Article

VL - 122

SP - 799

EP - 808

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -